Table 3 Variables associated with overall survival in the univariate analysis
From: Thymostimulin in advanced hepatocellular carcinoma: A phase II trial
Variables | No. of patients | Median survival (months ± SD) | p-value |
|---|---|---|---|
Overall | 44 (100%) | 11.5 ± 1.8 | |
No cirrhosis/Child A | 30 (68%) | 13.7 ± 1.7 | |
Child B | 9 (21%) | 6.3 ± 2.8 | p = 0.01 |
Child C | 5 (11%) | 0.4 ± 0.1 | |
Okuda stage I | 13 (29%) | 15.7 ± 6.4 | |
Okuda stage II | 28 (64%) | 10.4 ± 1.7 | p < 0.001 |
Okuda stage III | 3 (7%) | 0.4 ± 0.0 | |
CLIP 0 | 2 | 37.1* | |
CLIP 1 | 10 | 13.7 ± 2.7 | |
CLIP 2 | 15 | 13.6 ± 2.7 | p < 0.001 |
CLIP 3 | 10 | 8.1 ± 1.6 | |
CLIP 4–6 | 7 | 0.5 ± 0.1 | |
AFP < 400 ng/ml | 29 (66%) | 16.2 ± 3.5 | p < 0.001 |
AFP > 400 ng/ml | 15 (34%) | 6.3 ± 2.6 | |
thymostimulin only | 19 (43%) | 10.1 ± 4.7 | p = 0.1 |
additional therapy modalities | 25 (57%) | 13.7 ± 2.1 | |
no vascular invasion | 30 (68%) | 11.5 ± 2.2 | p = 0.3 |
with vascular invasion | 14 (32%) | 10.8 ± 2.8 | |
no extrahepatic metastases | 35 (79%) | 13 ± 1.7 | p = 0.1 |
with extrahepatic metastases | 9 (21%) | 8 ± 7.5 |